The HIV/AIDS pandemic has been a challenging U.S. public health issue, with an impact on conditions that fall within the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Responding to this challenge, the NIAMS has published a Notice of Special Interest (NOSI) to promote research opportunities on HIV/AIDS (NOT-AR-20-005). Applications are being accepted through January 7, 2022.
The NOSI alerts potential applicants to the NIAMS of an area of special interest in HIV/AIDS-associated comorbidities that are within the Institute’s mission. The NIH has provided the largest public investment in HIV/AIDS research globally. In line with overall NIH efforts, NIAMS encourages observational, translational, and basic/pre-clinical research focusing on how the presence or treatment of HIV/AIDS impacts systemic rheumatic, musculoskeletal and skin disease progression and pathogenesis with a focus on utilization of existing HIV cohorts and repositories.
Projects should meet the NIH HIV/AIDS Research Priorities and Guidelines (NOT-OD-20-018). NIAMS is interested in supporting studies focused on, but not limited to:
- Delineating the impact of viral or host factors or interaction of these two factors, or anti-retroviral therapy (ART) in people living with HIV (PLWH) on accelerating or worsening or early-onset of comorbidities.
- Studying the prevalence and risk assessment and management of HIV/AIDS-associated comorbidities in PLWH.
- Identifying etiological targets or biomarkers along with mechanistic action for diagnosis or preclinical candidate therapeutic evaluation/development.
Examples of HIV/AIDS-associated comorbidities that are within the NIAMS mission are:
- Musculoskeletal pain.
- Muscle diseases (e.g., sarcopenia, cachexia, muscular dystrophy).
- Cartilage degeneration (e.g., osteoarthritis).
- Bone diseases (e.g., osteoporosis, osteopenia).
- Bone fracture.
- Arthritis and other rheumatic diseases (e.g., reactive arthritis, psoriatic arthritis, septic arthritis).
- Dermatological manifestations.
For more information on this initiative, please see:
For inquiries, please contact:
Heiyoung Park, Ph.D.
Program Director, Scleroderma, Fibrosis, and Autoinflammatory Disease Program, NIAMS